CIK 0001133416 · Non-accelerated filer<br>Smaller reporting company
GALECTIN THERAPEUTICS INC
Sign in to watch- Ticker
- GALT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- operating
- EIN
- 043562325
- Phone
- 678-620-3186
- Business address
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA, 30071
- Former names
- PRO PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-26 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −2,037 | 100,000 | ||
| 2026-06-26 | Jamil Khurram Chief Medical Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,533 | 47,467 | ||
| 2026-06-23 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +7,557 | $1.23 | $9K | 7,557 |
| 2026-06-23 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −7,557 | $3.14 | $24K | 0 |
| 2026-06-23 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −7,557 | 32,500 | ||
| 2026-05-26 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 | +568 | $1.23 | $699 | 568 |
| 2026-05-26 | Jamil Khurram Chief Medical Officer | Sale 10b5-1 | −568 | $3.10 | $2K | 0 |
| 2026-05-26 | Jamil Khurram Chief Medical Officer | Option exercise · Stock option (right to buy) 10b5-1 | −568 | 40,057 | ||
| 2026-03-12 | Brem Henry Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-02-06 | ELDRED KARY Director | Purchase | +300 | $2.70 | $810 | 65,682 |
| 2026-01-16 | LEWIS JOEL President and CEO | Grant or award · Stock option (right to buy) | +91,000 | 91,000 | ||
| 2026-01-16 | CARSON BENJAMIN SR Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | Zordani Richard A. Jr. Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | Jamil Khurram Chief Medical Officer | Grant or award · Stock option (right to buy) 10b5-1 | +65,000 | 65,000 | ||
| 2026-01-16 | Jamil Khurram Chief Medical Officer | Grant or award · Restricted Stock Unit 10b5-1 | +100,000 | 100,000 | ||
| 2026-01-16 | FREEMAN KEVIN D Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | ELDRED KARY Director | Grant or award · Stock option (right to buy) | +60,000 | 60,000 | ||
| 2026-01-16 | LEWIS JOEL President and CEO | Grant or award · Stock option (right to buy) 10b5-1 | +84,000 | 65,000 | ||
| 2026-01-16 | LEWIS JOEL President and CEO | Grant or award · Restricted Stock Unit 10b5-1 | +120,000 | 100,000 | ||
| 2026-01-16 | CALLICUTT JACK W Chief Financial Officer | Grant or award · Stock option (right to buy) 10b5-1 | +65,000 | 65,000 |
Page 2 of 15 · 291 trades